Advancing the global public health agenda for NAFLD: a consensus statement
Open accessThe DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD. Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease with a substantial burden worldwide. In this Consensus Statement, a global multidisciplinary group of experts develop consensus statements and recommendations addressing a broad range of topics on NAFLD to raise awareness and spur action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citation2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citationExpanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078
Research works printed but not linked: 2
- Lazarus, J. V. et al. The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge? Int. Liver Congr. 75 (Suppl. 2), 23–26 (2021).
- Grime, M. M. & Wright, G. in Wiley StatsRef: Statistics Reference Online 1–6 (Wiley, 2011).
Cited by
Items 301–400 of 807
Zhang, M., Zhang, S., Wu, H., Xu, L., Gao, P., Gao, Y., Fan, W., & Song, S. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.06.042 · Cited by 15
Xiao, T., Liu, H., Tian, N., Lian, L., Miao, K., Li, Y., Chen, L., Yuan, H., Du, M., Wu, S., et al. (2025) · Liver International · doi:10.1111/liv.70208 · Cited by 14
“Metabolic dysfunction-associated steatotic liver disease (MASLD) is a disease affecting up to 30%–35% of the global adult population [8, 9].”
Self-citationSu, Y., Choi, H.-S., Choi, J.-H., Kim, H.-S., Lee, G.-Y., Cho, H.-W., Choi, H., Jang, Y., & Seo, J. (2023) · Nutrients · doi:10.3390/nu15020427 · Cited by 14
“evertheless, there are fe effecti e r s i cli ical trials, which indicates the need to pursue safe compounds as alternative therapies for treating NAFLD [2,4].”
BackgroundKamari, N., Moradinazar, M., Qasemi, M., Khosravy, T., Samadi, M., & Abdolahzad, H. (2023) · Food Science & Nutrition · doi:10.1002/fsn3.3218 · Cited by 14
Nonalcoholic Fatty Liver Disease in Latin America and Australia
Castellanos, M., Pal, S. C., Arrese, M. A., Arab, J. P., George, J., & Méndez‐Sánchez, N. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.015 · Cited by 14
Self-citationTimaná, J., Chahuara, H., Basavarajappa, L., Basarab, A., Hoyt, K., & Lavarello, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-33964-9 · Cited by 14
Zhang, D., Wu, S., Lan, Y., Chen, S., Wang, Y., Sun, Y., Lu, Y., Liao, W., & Wang, L. (2023) · Chemosphere · doi:10.1016/j.chemosphere.2023.139598 · Cited by 16
Țâru, M.-G., & Lupșor‐Platon, M. (2023) · Cancers · doi:10.3390/cancers15164097 · Cited by 15
James, M., Smuk, M., Rahman, N., Black, G. B., & Alazawi, W. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70080 · Cited by 13
“…cirrhosis, decompensation, and the development of hepatocellular carcinoma (HCC), all of which have a substantial impact on health-related quality of life [4], morbidity, and mortality [5], with the greatest socioeconomic burden of MASLD associated with the late stages of the disease [6].”
Padiadpu, J., García‐Jaramillo, M., Newman, N. K., Pederson, J. W., Rodrigues, R. R., Li, Z., Singh, S. P., Monnier, P., Trinchieri, G., Brown, K., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202318367 · Cited by 14
“Metabolic-associated fatty liver disease (MAFLD) or nonalcoholic steatohepatitis (NASH), type 2 diabetes and cardio-vascular diseases are all associated with obesity and a sedentary lifestyle (Marjot et al , 2020; Lazarus et al , 2022).”
BackgroundDuran‐Bertran, J., Rusu, E. C., Barrientos‐Riosalido, A., Bertran, L., Mahmoudian, R., Aguilar, C., Riesco, D., Martínez, S., Chicote, J. U., Sabench, F., et al. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14123 · Cited by 13
Tran, S., Zou, B., Lee, K., Kam, L. Y., Yeo, Y. H., Henry, L. L., Cheung, R. C., & Nguyen, M. H. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18024 · Cited by 13
“32,33 This suggestion is even more imperative when reviewing the results for those with cryptogenic cirrhosis since cryptogenic cirrhosis is often referred to as “burned out non-alcoholic steatohepatitis (NASH)” the more advanced form of NAFLD.”
BackgroundKwon, H., Kim, M.-G., Oh, S.-H., Kim, Y., Jung, G., Lee, H.-J., Kim, S.-Y., & Bae, H. (2024) · Diagnostics · doi:10.3390/diagnostics14121237 · Cited by 14
Self-citationImpact of Lactobacillaceae supplementation on the multi-organ axis during MASLD
Santos, A. A., Duarte, R., Duarte, M., Arella, F., Marques, V., Roos, S., & Rodrigues, C. M. P. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122948 · Cited by 13
Lv, D., Han, N., Yuan, M., Huang, W., Yan, L., & Tang, H. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.189 · Cited by 14
Scoparone alleviates nonalcoholic fatty liver disease by modulating the PPARα signaling pathway
Huang, P., Yang, L., Liu, T., Jiang, Y., Chen, Z., Song, H., & Zheng, P. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177033 · Cited by 16
Gu, Y., Guo, C., Liu, Z., Han, X., Han, X., Zhang, X., Zhao, S., Wang, H., & Zhang, T. (2025) · Public Health · doi:10.1016/j.puhe.2025.02.028 · Cited by 13
Emerging Roles of Periodontal Pathogen–Derived Outer Membrane Vesicles in NAFLD
Lv, C., Shi, K., Guo, Y.-D., Guo, Z., Luo, P., Wang, L., Wu, Z., & Yu, P. L. (2025) · International Dental Journal · doi:10.1016/j.identj.2025.03.029 · Cited by 13
Wan, M., Zhao, W., Cai, Y., He, Q., & Zeng, J. (2025) · American Journal of Translational Research · doi:10.62347/zwsr4476 · Cited by 13
Chiu, C., Chang, C., Lin, J., Chen, C., Chyau, C.-C., & Peng, R. Y. (2022) · Antioxidants · doi:10.3390/antiox11050898 · Cited by 13
Rajendra, V. K. P., Kurapati, S., Balineni, S. K., & Gogineni, N. T. (2022) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v12i7.958 · Cited by 14
de Freitas, L. B. R., Longo, L., Filippi‐Chiela, E. C., de Souza, V. E. G., Behrens, L. M. P., Pereira, M. H. M., Leonhard, L. C., Zanettini, G., Pinzon, C. E., Luchese, E., et al. (2022) · Biomolecules · doi:10.3390/biom12121773 · Cited by 14
“It is the most common chronic liver disease worldwide, and massively affects health and economic systems [2,4,5].”
Marschner, R. A., Roginski, A. C., Ribeiro, R. T., Longo, L., de Freitas, L. B. R., Alvares-da-Silva, M., & Wajner, S. M. (2023) · Cells · doi:10.3390/cells12071022 · Cited by 15
“The prevalence of MAFLD is around 25–38% of the world population [2,3].”
BackgroundSelf-citationNASH Drug Development: Seeing the Light at the End of the Tunnel?
Chen, Y. Q. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00058 · Cited by 13
Petroni, M. L., Colosimo, S., Brodosi, L., Armandi, A., Bertini, F., Montesi, D., Bugianesi, E., & Marchesini, G. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17768 · Cited by 13
Self-citationShea, S., Lionis, C. D., Atkinson, L., Kite, C., Lagojda, L., Chaggar, S. S., Kyrou, I., & Randeva, H. S. (2022) · Livers · doi:10.3390/livers3010001 · Cited by 16
Fan, Y., Ren, Y., Deng, L., Lv, D., Chen, J., Ling, Y., Tu, J., Xu, X., Wang, D., & Cai, Z. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113641 · Cited by 12
Hong, J., & Kim, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.008 · Cited by 14
From NAFLD to MASLD: transforming steatotic liver disease diagnosis and management
Iruzubieta, P., Jiménez-González, C., Cabezas, J., & Crespo, J. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.143 · Cited by 12
Self-citationPathogenesis and Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
Lucaciu, R. L., Coste, S. C., Hangan, A. C., Iancu, M., Orasan, O. H., Cozma, A., Bogdan, S. G., & Procopciuc, L. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125717 · Cited by 14
“It represents a generic name for several liver diseases, which include non-alcoholic fatty liver (NAFL), simple fatty liver (SFL), non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC) [2].”
Tang, Y., & Gu, C. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1624440 · Cited by 12
“Despite NAFLD’s intricate associations with prevalent noncommunicable diseases (NCDs) and substantial overlap in public health management pathways, its exclusion from the World Health Organization’s Global Action Plan for NCDs has perpetuated systemic neglect (12).”
Tang, X., Zhou, Y., Xia, L., Lin, X., Zhu, Y., Chen, M., Wang, J., & Li, Y. (2025) · Molecules · doi:10.3390/molecules30153066 · Cited by 13
“MASH is increasingly recognized as a significant global health concern, with epidemiological studies indicating a rising prevalence [6–8].”
Hepatic transcriptome signatures in mice and humans with nonalcoholic fatty liver disease
Ding, Y., Dai, X., Bao, M., Xing, Y., Liu, J., Zhao, S., Liu, E., Yuan, Z., & Bai, L. (2023) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12338 · Cited by 13
Cheng, W., Chen, H.-F., Cheng, H., & Li, C. (2024) · Epidemiology and Health · doi:10.4178/epih.e2024024 · Cited by 12
“However, for a disease affecting 20% to 25% of the global adult population and with serious potential health consequences [5], definition via negative criteria seems counterintuitive.”
BackgroundJun, H., Liu, S., Knights, A. J., Zhu, K., Ma, Y., Gong, J., Lenhart, A. E., Peng, X., Huang, Y., Ginder, J. P., et al. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002728 · Cited by 12
Mitsinikos, T., Aw, M., Bandsma, R., Godoy, M., Ibrahim, S. H., Mann, J. P., Memon, I. A., Mohan, N., Mouane, N., Porta, G., et al. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12399 · Cited by 15
Self-citationTong, Y., Zhu, W., Wen, T., Mukhamejanova, Z., Xu, F., Xiang, Q., & Pang, J. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.2c00259 · Cited by 13
Ishii, Y., Tsuchiya, A., Natsui, K., Koseki, Y., Takeda, N., Tomiyoshi, K., Yamazaki, F., Yoshida, Y., Shimbo, T., Tamai, K., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13825 · Cited by 13
“A smaller proportion of people develop non‐alcoholic steatohepatitis (NASH) with fibrosis, which eventually progresses to cirrhosis and hepatocellular carcinoma (HCC).(1,2) To date, therapy for NAFLD/NASH with peroxisome proliferator‐activated receptor agonists, glucagon‐like peptide‐1 receptor (GLP‐1R) agonists, or s…”
BackgroundNoninvasive Algorithms for the Case Finding of “At-Risk” Patients with NAFLD
Castéra, L., & Boursier, J. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1751081 · Cited by 12
Yang, M., Xu, Y., Hu, C., Zhang, S., Kuang, M., & Zou, Y. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01660-8 · Cited by 11
“This dangerous situation was also explicitly mentioned in a recent statement of the NAFLD Consensus Consortium and advocated the development of a NAFLD public health roadmap to advance the global public health agenda for NAFLD [12].”
BackgroundLiu, Z., Huang, H., Xie, J., Hou, L., & Xu, C. (2023) · Nutrition Journal · doi:10.1186/s12937-023-00897-y · Cited by 12
“NAFLD is a benign condition for most patients [27].”
BackgroundErgenç, İ., Kara, E., Yilmaz, M. E., Demirtaş, C. Ö., Keklikkıran, Ç., Daş, T., Büyük, Y., Çelikel, Ç., Aslıyüksek, H., & Yilmaz, Y. N. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34915 · Cited by 13
“In the context of steatohepatitis, mortality and morbidity risk closely correlate with histological severity, significantly increasing with worsening fibrosis [18,19].”
BackgroundSelf-citationRomano, J., Burnside, J., Sebastiani, G., Ramji, A. S., Patel, K., Swain, M. G., & Saeed, S. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101757 · Cited by 13
Self-citationKhan, K. S., Fawzy, M. M., CHIEN, P. F. W., Geary, M. P., Bueno‐Cavanillas, A., Núñez‐Núñez, M., Zamora, J., Bedaiwy, M. A., Serour, G. I., D’Hooghe, T., et al. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.16118 · Cited by 11
Askeland, A., Rasmussen, R. W., Gjela, M., Frøkjær, J. B., Højlund, K., Mellergaard, M., & Handberg, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-85508-y · Cited by 11
El‐Kassas, M., Villota‐Rivas, M., Alswat, K., Al-Naamani, K. M., Yilmaz, Y. N., Labidi, A., Sanai, F. M., Awad, A., Akroush, M., Alqahtani, S. A., et al. (2025) · Liver International · doi:10.1111/liv.70108 · Cited by 11
“Building on past global efforts [20, 22, 23], this study aimed to establish a consensus-driven research and action priority agenda for MASLD within the MENA region by leveraging the expertise of a regional multidisciplinary panel.”
InfluentialSelf-citationRising burden of MASLD and CKM syndrome in Asia: A decade of trends and future projections
Duo, T., Wen, Y., Bian, Y., Wang, Y., Zhang, X., Ju, J., Lu, Y., Wang, Z., Wang, J., & Yang, B. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156549 · Cited by 12
Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma
Vachher, M., Bansal, S., Kumar, B., Yadav, S., Arora, T. K., Wali, N. M., & Burman, A. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30252 · Cited by 11
Shi, H., Prough, R. A., McClain, C. J., & Song, M. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109189 · Cited by 11
Self-citationLi, W., Twaddle, N. C., Spray, B. J., Nounamo, B., Monzavi‐Karbassi, B., & Hakkak, R. (2023) · Journal of Medicinal Food · doi:10.1089/jmf.2022.0100 · Cited by 11
“12 The connection between chronic inflammation and NAFLD is well-established.”
Zhang, Q., Chen, S., Ke, Y., Li, Q., Shen, C., Ruan, Y., Wu, K., Hu, J., & Liu, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1073498 · Cited by 11
Ciccarelli, G., Giuseppe, G. D., Cinti, F., Moffa, S., Mezza, T., & Giaccari, A. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3668 · Cited by 11
Yao-Shan of traditional Chinese medicine: an old story for metabolic health
Yang, S., Yang, H., & Zhang, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1194026 · Cited by 13
“Currently, 25% of the world population is thought to have NAFLD (Younossi et al., 2019; Lazarus et al., 2022), and the national prevalence of NAFLD in China has exceeded 29% (Zhou et al.”
BackgroundExosomes: New Insights into the Pathogenesis of Metabolic Syndrome
Wang, N., Li, J., Hu, Z., Ngowi, E. E., Yan, B., & Qiao, A. (2023) · Biology · doi:10.3390/biology12121480 · Cited by 14
“NAFLD, like obesity and diabetes, is a highly prevalent global metabolic disease that affects about a quarter of the global adult population and poses a serious health burden [89].”
BackgroundYang, Z., Zhang, S., Liu, X., Shu, R., Shi, W., Qu, W., Liu, D., Cai, Z., Wang, Y., Cheng, X., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100513 · Cited by 12
Díez-Sainz, E., Aranaz, P., Amri, E., Riezu‐Boj, J. I., Lorente‐Cebrián, S., & Milagro, F. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031721 · Cited by 13
“Therefore, therapeutic strategies aimed at controlling the early stages of the disease, such as hepatic lipid accumulation, could be crucial to prevent and/or reverse NAFLD [7].”
BackgroundSong, N., Li, H., Tang, Q., Luo, S., Shi, Z., Zhao, Q., Li, R., Chen, Y., Cai, X., & Jiang, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01764 · Cited by 11
Hwang, S., Choi, Y., Wang, J., & Son, C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116250 · Cited by 11
Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease
Barberá, A., White, T. M., Arora, A. K., Henry, L. L., Lazarus, J. V., & Younossi, Z. M. (2024) · Seminars in Liver Disease · doi:10.1055/a-2435-2091 · Cited by 11
Self-citationMouskeftara, T., Kalopitas, G., Liapikos, T., Arvanitakis, K., Theocharidou, E., Germanidis, G. S., & Gika, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313067 · Cited by 11
Song, Z., Gu, H.-Q., & Xu, C. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1540903 · Cited by 10
Brouwer, W. P., Vonghia, L., Thiele, M. S., Schattenberg, J. M., Anastasiou, F., Beckmann, S., Bugianesi, E., Castéra, L., Caussy, C., Cordie, A., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101798 · Cited by 12
“Figs 4 and 5 summarise the management of SLD after identification of non-advanced disease.”
Self-citationKeating, S. E., Croci, I., Wallen, M. P., Cox, E. R., Coombes, J. S., Burton, N. W., Macdonald, G. A., & Hickman, I. J. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00091s · Cited by 11
Self-citationKlein, R. J., Rodriguez, G. M. V., Rotman, Y., & Brown, R. J. (2023) · Liver International · doi:10.1111/liv.15707 · Cited by 10
García-Morena, D., Fernández-Cantos, M. V., Lopez-Escalera, S., Lok, J., Iannone, V., Cancellieri, P., Maathuis, W., Panagiotou, G., Aranzamendi, C., Aidy, S. E., et al. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10219-1 · Cited by 10
“The high prevalence of MAFLD and other metabolic disorders and the rapid increase in prevalence over the last decade calls for immediate action in addressing the onset and progression of the disease [10, 15, 61].”
Wang, W., Qin, J., Bai, S., Tian, J., Zhou, Y., Qin, X., & Gao, X. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119005 · Cited by 12
El‐Ashmawy, N. E., Al‐Ashmawy, G. M., Kamel, A. A., & Khedr, E. G. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167666 · Cited by 10
He, B., Chen, Z., Nie, Y., Luo, M., Xu, S., Yan, J., & Chen, Z. (2022) · Journal of Immunology Research · doi:10.1155/2022/6588144 · Cited by 10
“NAFLD also directly in fl uences a quarter of adults worldwide, and there is a trend of younger episodes [28].”
Liu, Z., Huang, H., Xie, J., & Xu, C. (2023) · Nutrients · doi:10.3390/nu15020271 · Cited by 12
“For the majority of patients, NAFLD is a benign condition [7].”
BackgroundLutsiv, T., McGinley, J. N., Neil, E. S., Foster, M. T., & Thompson, H. J. (2023) · Nutrients · doi:10.3390/nu15030526 · Cited by 11
“In turn, 20–25% of people with MASH within ten years develop advanced fibrosis with severely impaired liver function termed cirrhosis, the end-stage liver disease, markedly increasing the probability of hepatocellular carcinoma (HCC) development [5,9].”
BackgroundSwain, M. G., Pettersson, B., Meyers, O. I., Venerus, M., & Oscarsson, J. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000036 · Cited by 10
“By sharing personal experiences of NASH with other patients, and receiving some educational support from health care professionals, patients may understand their condition better as well as learn strategies for managing their condition better.[29] It is important to recognize the concepts that were reported by few pat…”
BackgroundSelf-citationMedical imaging in the assessment of cardiovascular disease risk
Alcántara, J. M. A., Idoate, F., & Labayen, I. (2023) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000960 · Cited by 10
Ruan, X., Zhang, X.-M., Liu, L., & Zhang, J. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2231544 · Cited by 10
Pansa, C. C., Molica, L. R., de Oliveira-Júnior, F. C., Santello, L. C., & Moraes, K. C. M. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23595 · Cited by 9
Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease
Xuan, W., Song, D., Hou, J., & Meng, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1505117 · Cited by 10
Yang, X., Kuang, G., Gong, X., Xie, H., Lin, Y., Zhang, X., Chen, Z., Wan, J., & Li, Z. (2025) · Phytotherapy Research · doi:10.1002/ptr.8443 · Cited by 9
“…by excessive fat deposition in hepatocytes or metabolic disorders with a global prevalence of about 25%, and it has developed into the most predominant etiologic factor of chronic liver disease and the main cause of end-stage liver failure (Lazarus et al. 2022; Powell, Wong, and Rinella 2021).”
Liang, X.-M., Lai, K., Li, X.-H., Li, Y., Xing, Z.-M., & Gui, S.-Q. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02518-5 · Cited by 7
“The progression of NAFLD can lead to serious liver complications, including cirrhosis and even hepatocellular carcinoma [5, 6].”
Liu, S.-Y., Zhang, X.-W., Gao, G., Liu, C., Chen, H., Fu, Z., Xu, J., Wang, Z., Zhang, Z., & Xie, Z. (2025) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-025-3832-y · Cited by 10
Self-citationMulti-target regulation by artemether in MAFLD through EGFR/HSP90 pathways
Xu, J., Huangfu, B., Wang, T., Ren, X., Zhang, F., Huang, K., & He, X. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.07.048 · Cited by 11
“MAFLD primarily results from excessive hepatic fat accumulation due to dietary surplus [2].”
EVA1A Regulates Hepatic Lipid Homeostasis by Modulating CD36 Expression and Its Palmitoylation
Yang, D., Li, L., Zang, K., Ma, W., Yang, Y., Sun, Y., Zhang, B., Gong, Z., Mei, Y., Du, Q., et al. (2025) · Research · doi:10.34133/research.1001 · Cited by 9
“Fatty liver can lead to systemic metabolic dysfunction and evolve through a series of stages—from steato-hepatitis and fibrosis to cirrhosis—ultimately culminating in hepatocellular carcinoma (HCC), an irreversible and life-threatening condition [ 5 , 6 ].”
Holleboom, A. G., Francque, S., Cusi, K. J., & Caussy, C. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100424 · Cited by 11
“Based on all the progress made, improving clinical care is currently shaping up [10 – 12] to address the increasing number of patients with advanced stages of MASLD.”
Self-citationAbbas, M. S., Dandamudi, M., Rehman, T., Faizan, M. A., Zahra, I., Mojica, J. C., Ahmed, M. M. A., Bai, K., Shakeel, I., Shahzad, Z., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01797-0 · Cited by 12
Demnitz‐King, H., Banerjee, S., Cooper, C., Kenten, C., Phillips, R., Zabihi, S., Birks, Y. F., Brayne, C., Browning, S., Carroll, C., et al. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-025-01173-9 · Cited by 9
“that reached consensus were graded further with a commonly used Delphi classification system 32,33 and assigned one of four grades: U (unanimous, 100% agreement), A (90–99% agreement), B (78–89% agreement) or C (67–77% agreement).”
Çelik, M. N., Dazıroğlu, M. E. Ç., Atabılen, B., Nanì, M. F., Romano, B., Ağagündüz, D., & Capasso, R. (2026) · Food Research International · doi:10.1016/j.foodres.2026.118945 · Cited by 11
Steinmann, S., Hartl, J., Weidemann, S. A., Füssel, K., Kroll, C., Sebode, M., Lohse, A. W., & Schramm, C. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100898 · Cited by 9
Wu, X., Arya, R. K., Huang, E., McMullen, M. R., & Nagy, L. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1267996 · Cited by 9
“Obesity is highly associated with the development of NAFL/NASH, with up to 70-80% of obese individuals having some degree of fatty liver disease (30).”
BackgroundMemedovich, K. A., Shaheen, A. A., Swain, M. G., & Clement, F. M. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.05.010 · Cited by 9
“19 – 21 Continuing to promote these interventions will hopefully prevent both MASLD and associated comorbidities, including obesity and diabetes.”
BackgroundSelf-citationGuo, Z., Yao, Z., Huang, B., Wu, D., Li, Y., Chen, X., Lu, Y., Wang, L., & Lv, W. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112821 · Cited by 10
Salmanizadeh, F., Sabzevari, S., Shafieipour, S., Zahedi, M. J., & Sarafinejad, A. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03921-z · Cited by 9
“It is essential to treat and manage NAFLD because excessive liver fat is an independent risk factor in developing other conditions like diabetes and cardiovascular diseases [5], making NAFLD a significant health problem worldwide [7].”
Bao, X., Ma, X., Huang, R., Chen, J., Xin, H., Zhou, M., Li, L., Tong, S., Zhang, Q., Shui, G., et al. (2022) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjac055 · Cited by 12
“A hallmark of fatty liver disease is the excessive deposition of lipid droplets in the liver ( Samuel and Shulman, 2019 ; Seebacher et al., 2020 ; Lazarus et al., 2021 ; Mashek, 2021 ) .”
Romero‐Gómez, M., Aller, R., & Martín, F. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1757711 · Cited by 11
Self-citationHemminki, K., Sundquist, K., Sundquist, J., Försti, A., Liška, V., Hemminki, A., & Li, X. (2023) · Cancers · doi:10.3390/cancers15123092 · Cited by 9
Li, J., Song, H., Chen, Z., Qiumin, Y., Yang, Z., Yan, C., & Zhong, C. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113631 · Cited by 9
Drozdov, I. A., Szubert, B., Rowe, I. A. C., Kendall, T. J., & Fallowfield, J. A. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101528 · Cited by 8
Self-citationMulti-omics approaches to explore the therapeutic mechanism for ginsenoside Rg1 against MASLD
Wang, Z., Wang, Y., Zhang, J., Yin, K.-L., Luo, H., & Huang, W. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152161 · Cited by 8
Wang, F., Zheng, X., Ni, X., & Li, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-09073-0 · Cited by 8
Vallejo, U. C., & Espinoza, G. W. F. (2025) · ESPACIOS · doi:10.48082/espacios-a25v46n05p09 · Cited by 12
Huybrechts, T., Franck, K., Steenackers, E., & Hul, W. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211054 · Cited by 8
“MASLD includes a spectrum of liver conditions, from hepatic steatosis, a milder and reversible form, to hepatocellular carcinoma (HCC) (Figure 1) [2,4–6].”
Sriperumbuduri, S., Saravanan, P. B., Gupta, G., & Sanyal, A. J. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.103757 · Cited by 12
“24,29,30 Plant-based diets—rich in fruits, vegetables, whole grains, and low-fat dairy—help mitigate hypertension, diabetes, and obesity, slow eGFR decline, reduce proteinuria and metabolic acidosis, and improve quality-of-life measures, collectively supporting their role in delaying CKD…”
Chen, C.-C., Hsu, L., Chen, K., Chiu, K., Kung, C.-P., Li, S., Chen, C., & Huang, K. (2024) · Cell Calcium · doi:10.1016/j.ceca.2024.102895 · Cited by 8
Metadata
- Authors
- Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., Francque, S., George, J., Hagström, H., Huang, T. T.-K., Ismail, M. H., Kautz, A., Sarin, S. K., Loomba, R., Miller, V., Newsome, P. N., Ninburg, M., Ocama, P., Ratziu, V., Rinella, M., Romero, D., Romero-Gómez, M., Schattenberg, J. M., Tsochatzis, E. A., Valenti, L., Wong, V. W.-S., Yilmaz, Y., Younossi, Z. M., Zelber-Sagi, S., the NAFLD Consensus Consortium, Åberg, F., Adams, L., Khatry, M. S. A., Naamani, K. A., Murillo, O. A., Allen, A. M., Alnaser, F., Alqahtani, S. A., Alswat, K., Alvaro, D., Andrade, R. J., Arrese, M., Awuku, Y. A., Ayesha, M., Baatarkhuu, O., Bakieva, S., Basu, R., Bataller, R., Bedri, S., Bosi, E., Bourliere, M., Bruha, R., Bugianesi, E., Burra, P., Buti, M., Byrne, C. D., Calleja, J. L., Carrieri, P., Carter, F., Fernandez, M. I. C., Castillo-Lopez, G., Castro-Narro, G. E., Chan, H. L. Y., Chan, W.-K., Chang, Y., Colombo, M., Coppell, K. J., Corey, K., Craxi, A., Cryer, D., Dassanayake, A., Martins, A. D. A. S., de Ledinghen, V., DelPrato, S., Demaio, A., Desalegn, H., Dillon, J., Duseja, A., Dorairaj, P., Ekstedt, M., El Kassas, M., Elsanousi, O. M., Esmat, G., Fan, J.-G., Farpour-Lambert, N., Flisiak, R., Fouad, Y., Fuchs, M., Gani, R. A., Gerber, L., Ghazinyan, H., Gheorghe, L., Goh, G. B.-B., Grønbæk, H., Gulnara, A., Hamid, S., Hebditch, V., Hickman, I. J., Hocking, S. L., Hunyady, B., Idilman, R., Isakov, V. A., Jamal, M. H., Jepsen, P., Iskandar, N. J., Song, M. J., Sudhamshu, K. C., Kakizaki, S., Kalamitsis, G., Kanwal, F., Kao, J.-H., Kaplan, L., Kawaguchi, T., Khader, Y., Kim, S. U., Kodjoh, N., Koek, G., Koike, K., Komas, N. P., Korenjak, M., Kugelmas, M., Labidi, A., Lange, N. F., Lavine, J. E., Lazo, M., Lee, N., Lesmana, C. R. A., Liu, C.-J., Long, M. T., Lopez-Jaramillo, P., Malekzadeh, R., Mahtab, M. A., Marchesini, G., Marinho, R., Vázquez, S. E. M., Mateva, L., Nlombi, C. M., Melin, P., Mikolasevic, I., Milovanovic, T., Musso, C., Nakajima, A., Nava, E., Nersesov, A. V., Nikolova, D., Norris, S., Novak, K., Oben, J., Ong, J. P., Onyekwere, C., Papatheodoridis, G., Paruk, I., Patel, K., Macedo, M. P., Penha-Gonçalves, C., Figueroa, M. P., Hofmann, W. P., Petta, S., de Oliveira, C. P. M. S., Puri, P., Pan, C. Q., Rac, M., Ralston, J., Ramji, A., Razavi, H., Alvares-da-Silva, M. R., Roberts, S., Roden, M., Rose, T., Rouabhia, S., Rovere-Querini, P., Rowe, I. A., Sadirova, S., Salupere, R., Saparbu, T., Sayegh, R., Sebastiani, G., Seki, Y., Selmo, J., Serme, A. K., Shaw, J. E., Shenoy, T., Sheron, N., Shibolet, O., Silva, M., Skrypnyk, I., Socha, P., Soriano, J., Spearman, C. W., Sridharan, K., Suárez, J. J., Sheriff, D. S., Sung, K.-C., Swain, M., Tacke, F., Taheri, S., Tan, S.-S., Tapper, E. B., Yki-Järvinen, H., Thiele, M., Shawa, I. T., Tolmane, I., Torres, E. A., Trauner, M., Treeprasertsuk, S., Turcanu, A., Valantinas, J., Vesterhus, M., Waked, I., Wild, S. H., Willemse, J., Wong, R. J., Xanthakos, S., Young, D. Y., Yu, M.-L., Zheng, K. I., Zeybel, M., & Zheng, M.-H.
- Affiliations
- Barcelona Institute for Global Health (ES)
- European Association for the Study of the Liver (CH)
- NIHR Newcastle Biomedical Research Centre (GB)
- Pontificia Universidad Católica de Chile (CL)
- University College London Hospitals NHS Foundation Trust (GB)
- Marqués de Valdecilla University Hospital (ES)
- Veterans Health Administration (US)
- University of Washington (US)
- University of Antwerp (BE)
- The University of Sydney (AU)
- Karolinska Institutet (SE)
- City University of New York (US)
- King Fahd Hospital of the University (SA)
- Institute of Liver and Biliary Sciences (IN)
- University of California San Diego (US)
- University of California, Berkeley (US)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Makerere University (UG)
- Université Paris Cité (FR)
- Northwestern University (US)
- The Graduate Center, CUNY (US)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- The Royal Free Hospital (GB)
- University of Milan (IT)
- Chinese University of Hong Kong (HK)
- Marmara University (TR)
- Inova Health System (US)
- University of Helsinki (FI)
- The University of Western Australia (AU)
- Mayo Clinic (US)
- Johns Hopkins University (US)
- King Saud University (SA)
- Sapienza University of Rome (IT)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- University of Health and Allied Sciences (GH)
- University of KwaZulu-Natal (ZA)
- Mongolian National University of Medical Sciences (MN)
- Ministry of Health of the Republic of Uzbekistan (UZ)
- University of Virginia (US)
- University of Pittsburgh (US)
- Ahfad University for Women (SD)
- Vita-Salute San Raffaele University (IT)
- University of Turin (IT)
- University of Padua (IT)
- University of Southampton (GB)
- Inserm (FR)
- University of the West Indies (BS)
- Universidad de Buenos Aires (AR)
- Union Hospital (HK)
- University of Malaya (MY)
- Kangbuk Samsung Hospital (KR)
- IRCCS Ospedale San Raffaele (IT)
- University of Otago (NZ)
- Harvard University (US)
- University of Kelaniya (LK)
- University of Pisa (IT)
- St. Paul's Hospital Millennium Medical College (ET)
- University of Dundee (GB)
- Post Graduate Institute of Medical Education and Research (IN)
- World Heart Federation (CH)
- Linköping University (SE)
- National Ribat University (SD)
- Cairo University hospitals (EG)
- Shanghai Jiao Tong University (CN)
- Medical University of Białystok (PL)
- Minia University (EG)
- Virginia Commonwealth University (US)
- University of Indonesia (ID)
- Carol Davila University of Medicine and Pharmacy (RO)
- Singapore General Hospital (SG)
- Aarhus University Hospital (DK)
- Aga Khan University (PK)
- British Liver Trust (GB)
- Princess Alexandra Hospital (AU)
- Kuwait University (KW)
- Hlabisa Hospital (ZA)
- Catholic University of Korea (KR)
- National Academy of Medical Sciences (NP)
- National Hospital Organization Takasaki General Medical Center (JP)
- Baylor College of Medicine (US)
- National Taiwan University Hospital (TW)
- Kurume University (JP)
- Jordan University of Science and Technology (JO)
- Yonsei University (KR)
- Université d'Abomey-Calavi (BJ)
- Maastricht University Medical Centre (NL)
- The University of Tokyo (JP)
- Institut Pasteur de Bangui (CF)
- Denver Public Library (US)
- Hôpital La Rabta (TN)
- University Hospital of Bern (CH)
- Columbia University (US)
- Drexel University (US)
- Wilton Park (GB)
- Boston University (US)
- University of Tehran (IR)
- Bangladesh Medical University (BD)
- University of Bologna (IT)
- Centro Hospitalar Lisboa Norte (PT)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- University Hospital St. Ivan Rilski (BG)
- University of Kinshasa (CD)
- Favaloro Foundation (AR)
- Yokohama City University (JP)
- Universidad Autónoma de Nuevo León (MX)
- Ss. Cyril and Methodius University in Skopje (MK)
- St. James's Hospital (IE)
- Ljubljana University Medical Centre (SI)
- Guy's Hospital (GB)
- University of the Philippines Manila (PH)
- Lagos State University (NG)
- National and Kapodistrian University of Athens (GR)
- University Health Network (CA)
- Universidade Nova de Lisboa (PT)
- University of Palermo (IT)
- NYU Langone Health (US)
- World Obesity Federation (GB)
- University of British Columbia (CA)
- Center for Disease Analysis (US)
- Alfred Health (AU)
- Düsseldorf University Hospital (DE)
- University of Leeds (GB)
- Tartu University Hospital (EE)
- Kyrgyz State Medical Academy (KG)
- Saint Joseph University (LB)
- McGill University Health Centre (CA)
- Yotsuya Medical Cube (JP)
- Baker Heart and Diabetes Institute (AU)
- King's College London (GB)
- Tel Aviv University (IL)
- Children's Memorial Health Institute (PL)
- Hospital Universitario de La Princesa (ES)
- University of Cape Town (ZA)
- Arabian Gulf University (BH)
- Universidad San Francisco de Quito (EC)
- University of Calgary (CA)
- Charité – Universitätsmedizin Berlin (DE)
- Weill Cornell Medical College in Qatar (QA)
- Hospital Selayang (MY)
- University of Michigan (US)
- University of Southern Denmark (DK)
- University of Malawi (MW)
- Riga East University Hospital (LV)
- University of Puerto Rico, Medical Sciences Campus (PR)
- Medical University of Vienna (AT)
- Chulalongkorn University (TH)
- Nicolae Testemițanu State University of Medicine and Pharmacy (MD)
- Vilnius University Hospital Santariskiu Klinikos (LT)
- Haraldsplass Diakonale Sykehus (NO)
- National Liver Institute (EG)
- University of Edinburgh (GB)
- Stanford Medicine (US)
- Cincinnati Children's Hospital Medical Center (US)
- National University of Singapore (SG)
- Kaohsiung Medical University (TW)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Koç University (TR)
- Corresponding author
- Lazarus, Jeffrey V.
- ORCID
- Lazarus, Jeffrey V.
- Mark, Henry E.
- Anstee, Quentin M.
- Arab, Juan Pablo
- Batterham, Rachel L.
- Castera, Laurent
- Cortez-Pinto, Helena
- Crespo, Javier
- Cusi, Kenneth
- Dirac, M. Ashworth
- Francque, Sven
- George, Jacob
- Hagström, Hannes
- Huang, Terry T.-K.
- Ismail, Mona H.
- Sarin, Shiv Kumar
- Loomba, Rohit
- Miller, Veronica
- Newsome, Philip N.
- Ninburg, Michael
- Ocama, Ponsiano
- Ratziu, Vlad
- Rinella, Mary
- Romero, Diana
- Romero-Gómez, Manuel
- Schattenberg, Jörn M.
- Tsochatzis, Emmanuel A.
- Valenti, Luca
- Wong, Vincent Wai-Sun
- Yilmaz, Yusuf
- Younossi, Zobair M.
- Åberg, Fredrik
- Adams, Leon
- Naamani, Khalid Al
- Allen, Alina M.
- Alqahtani, Saleh A.
- Alswat, Khalid
- Alvaro, Domenico
- Andrade, Raúl J.
- Arrese, Marco
- Awuku, Yaw Asante
- Baatarkhuu, Oidov
- Bakieva, Shokhista
- Basu, Rita
- Bataller, Ramon
- Bedri, Shahinaz
- Bosi, Emanuele
- Bugianesi, Elisabetta
- Burra, Patrizia
- Byrne, Christopher D.
- Carrieri, Patrizia
- Chan, Henry Lik Yuen
- Chan, Wah-Kheong
- Chang, Yoosoo
- Colombo, Massimo
- Coppell, Kirsten J.
- Corey, Kathleen
- Cryer, Donna
- Dassanayake, Anuradha
- Desalegn, Hailemichael
- Dillon, John
- Duseja, Ajay
- Ekstedt, Mattias
- Elsanousi, Osama M.
- Esmat, Gamal
- Fan, Jian-Gao
- Flisiak, Robert
- Fouad, Yasser
- Fuchs, Michael
- Gani, Rino A.
- Gerber, Lynn
- Gheorghe, Liana
- Goh, George Boon-Bee
- Grønbæk, Henning
- Hamid, Saeed
- Hickman, Ingrid J.
- Hocking, Samantha L.
- Jamal, Mohammad H.
- Jepsen, Peter
- Song, Myeong Jun
- Kakizaki, Satoru
- Kanwal, Fasiha
- Kao, Jia-Horng
- Kaplan, Lee
- Kawaguchi, Takumi
- Khader, Yousef
- Kim, Seung Up
- Kodjoh, Nicolas
- Koek, Ger
- Koike, Kazuhiko
- Komas, Narcisse Patrice
- Korenjak, Marko
- Kugelmas, Marcelo
- Labidi, Asma
- Lange, Naomi F.
- Lavine, Joel E.
- Lazo, Mariana
- Lee, Nancy
- Lesmana, Cosmas Rinaldi A.
- Liu, Chun-Jen
- Long, Michelle T.
- Malekzadeh, Reza
- Mahtab, Mamun Al
- Marchesini, Giulio
- Marinho, Rui
- Vázquez, Sophia E. Martínez
- Nlombi, Charles Mbendi
- Musso, Carla
- Nakajima, Atsushi
- Norris, Suzanne
- Oben, Jude
- Ong, Janus P.
- Onyekwere, Charles
- Papatheodoridis, George
- Paruk, Imran
- Patel, Keyur
- Macedo, M. Paula
- Figueroa, Marlene Pérez
- Hofmann, Wolf Peter
- Petta, Salvatore
- Puri, Puneet
- Pan, Calvin Q.
- Ralston, Johanna
- Ramji, Alnoor
- Razavi, Homie
- Roberts, Stuart
- Roden, Michael
- Rowe, Ian A.
- Sadirova, Shakhlo
- Sebastiani, Giada
- Seki, Yosuke
- Shaw, Jonathan E.
- Sheron, Nick
- Shibolet, Oren
- Silva, Marcelo
- Socha, Piotr
- Soriano, Joan
- Spearman, C. Wendy
- Sridharan, Kannan
- Sheriff, Dhastagir Sultan
- Sung, Ki-Chul
- Swain, Mark
- Tacke, Frank
- Taheri, Shahrad
- Tan, Soek-Siam
- Tapper, Elliot B.
- Thiele, Maja
- Shawa, Isaac Thom
- Tolmane, Ieva
- Torres, Esther A.
- Trauner, Michael
- Treeprasertsuk, Sombat
- Turcanu, Adela
- Valantinas, Jonas
- Vesterhus, Mette
- Waked, Imam
- Wild, Sarah H.
- Wong, Robert J.
- Xanthakos, Stavra
- Yu, Ming-Lung
- Zheng, Kenneth I.
- Zheng, Ming-Hua
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2021-10-27
- Volume
- 19
- Issue
- 1
- Pages
- 60-78
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W3208129759
- Cited by
- 757
- References
- 193
- Citations by year
- 2026: 100 · 2025: 156 · 2024: 163 · 2023: 201 · 2022: 127 · 2021: 9
- FWCI
- 19.36
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- UWA Profiles and Research Repository (UWA) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion, other-oa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Falk Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Celgene
- City University of New York
- Medpace
- Regeneron Pharmaceuticals
- European Federation of Pharmaceutical Industries and Associations
- Arrowhead Pharmaceuticals
- Medicines Company
- Galecto
- Intercept Pharmaceuticals
- NGM Biopharmaceuticals
- Coherus Biosciences
- National Institute for Health and Care Research (RP-2015-06-005)
- Rosetrees Trust
- Novo Nordisk
- Astellas Pharma
- Shionogi
- European Association for the Study of the Liver
- Novo Nordisk Fonden (NNF18OC0054612)
- Servier
- Julius Clinical
- Genentech
- Allergan
- Novartis Pharma
- Takeda Pharmaceuticals International
- Sanofi-Aventis Deutschland
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, public health policy, global health agenda, metabolic syndrome, non-communicable diseases, obesity, health system response, Delphi consensus
- MeSH terms
- Humans, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.